COLL - FDA updates safety requirements for opioid pain meds

2023-04-13 16:47:55 ET

• The U.S. Food and Drug Administration (FDA) issued new labeling requirements for opioid pain medications on Thursday, adding warnings about potential drug-induced reactions such as a rise in pain or pain sensitivity.
• Labeling changes include restrictions on the use of immediate -release opioids and extended-release/long-acting opioid analgesics.
• As reasons for its decision, the FDA noted that despite a sharp decline in prescriptions for opioid pain medicines, the patients who continue to use the meds often have leftover tablets that can lead to addiction and overdose.
• The FDA also noted that non-opioid medications and other treatments could relieve pain for multiple chronic pain conditions without the risks of opioid pain medicines.
• Currently, Dsuvia and Nucynta are sold as opioid pain meds by closely-held Alora Pharmaceuticals and Collegium Pharmaceuticals ( NASDAQ: COLL ), respectively. COLL began marketing Nucynta in 2018.

For further details see: